CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update
In: Expert Review of Vaccines, Jg. 20 (2021-04-09), S. 487-495
Online
unknown
Zugriff:
Introduction: HEPLISAV-B is a hepatitis B vaccine composed of rHBsAg mixed with a synthetic oligonucleotide containing CpG motifs that stimulate innate immunity through TLR9. This vaccine was recently approved by FDA in view of its superior efficacy.Areas covered: Published literature on HEPLISAV-B was critically reviewed. Four randomized controlled trials among 7,056 subjects receiving 2 doses of HEPLISAV-B and 3,214 subjects receiving 3 doses of Engerix-B showed superior seroprotection rate (SPR) (anti-HBs ≥10 mIU/mL) of 90-100%, compared with 71-90% in those receiving Engerix-B. Furthermore, the seroprotection rate was also significantly higher in HEPLISAV-B compared with Engerix-B recipients in persons with traditionally poor vaccine responses such as older adults, diabetics, and those with chronic kidney disease. The safety profiles among 9,871 subjects were similar between HEPLISAV-B and Engerix-B .Expert opinion: HEPLISAV-B, a CpG adjuvant mixed with HBsAg, is more efficacious and produced earlier seroprotection compared to existing vaccines, with a favorable safety profile. The shorter, two-dose regimen, earlier seroprotection, higher adherence, and a higher seroprotection rate, especially in populations with traditionally poor vaccine response, makes this an important therapeutic option in hepatitis B vaccination.
Titel: |
CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update
|
---|---|
Autor/in / Beteiligte Person: | Lim, Seng-Gee ; Lee, Guan-Huei |
Link: | |
Zeitschrift: | Expert Review of Vaccines, Jg. 20 (2021-04-09), S. 487-495 |
Veröffentlichung: | Informa UK Limited, 2021 |
Medientyp: | unknown |
ISSN: | 1744-8395 (print) ; 1476-0584 (print) |
DOI: | 10.1080/14760584.2021.1908133 |
Schlagwort: |
|
Sonstiges: |
|